Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 65 CHF Market Closed
Market Cap: 1B CHF
Have any thoughts about
Cosmo Pharmaceuticals NV?
Write Note

Cosmo Pharmaceuticals NV
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cosmo Pharmaceuticals NV
Cost of Revenue Peer Comparison

Comparables:
PRGO
JAZZ
AVDL
G
GHRS
OVB

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cosmo Pharmaceuticals NV
SIX:COPN
Cost of Revenue
-€43.6m
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-8%
Perrigo Company PLC
NYSE:PRGO
Cost of Revenue
-$2.8B
CAGR 3-Years
-2%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Cost of Revenue
-$424.2m
CAGR 3-Years
-6%
CAGR 5-Years
-29%
CAGR 10-Years
-14%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Cost of Revenue
-$5.1m
CAGR 3-Years
N/A
CAGR 5-Years
19%
CAGR 10-Years
N/A
G
GH Research PLC
NASDAQ:GHRS
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ovoca Bio PLC
LSE:OVB
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Cosmo Pharmaceuticals NV's Cost of Revenue?
Cost of Revenue
-43.6m EUR

Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Cost of Revenue amounts to -43.6m EUR.

What is Cosmo Pharmaceuticals NV's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%

Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for Cosmo Pharmaceuticals NV have been -15% over the past three years , -14% over the past five years , and -8% over the past ten years .

Back to Top